NCT03569267View on ClinicalTrials.gov

A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Cicatrix, Hypertrophic
Interventions
DRUG

OLX10010

A cell penetrating asymmetric siRNA (cp asiRNA)

DRUG

Placebo

Placebo

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit (CRU) Ltd., Leeds

Sponsors
All Listed Sponsors
lead

Olix Pharmaceuticals, Inc.

INDUSTRY

NCT03569267 - A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects | Biotech Hunter | Biotech Hunter